RxDoctor Payments Data

Richard Brown, MD

Cardiovascular Disease · Lees Summit, MONPI 1922055862

Payments from drug & device makers

$9,085in general payments, 2019–2025

Across 476 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$1K
  • Novartis$928
  • Biotronik Inc.$875
  • Boston Scientific$640
  • Boehringer Ingelheim$594
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$4695%
  • Food & beverage$8,57594%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,085 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$134,007
Medicare patients
1,033
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$390,065
XareltoRivaroxaban113$134,708
Repatha SureclickEvolocumab25$39,641
JardianceEmpagliflozin22$33,149
EntrestoSacubitril/Valsartan21$30,423
Praluent PenAlirocumab20$17,766
Repatha SyringeEvolocumab11$7,586
Metoprolol Succinate444$5,113
Flecainide Acetate110$4,706
Rosuvastatin Calcium213$3,863
Diltiazem 24hr Er (Cd)Diltiazem Hcl111$3,431
Losartan Potassium255$2,871
Carvedilol273$2,353
Atorvastatin Calcium160$1,952
Digoxin27$1,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$414$390,065339 claims
Johnson & JohnsonXarelto$1,020$134,708113 claims
Boehringer IngelheimJardiance$594$33,14922 claims
NovartisEntresto$928$30,42321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →